Methods: A large international collaboration collected BASDAI, CRP, HLA-B27 status and sacroiliac joints (SIJ) and spine radiographs. These were read centrally by two blinded readers using consensus on the modified New York criteria. mSASSS and PASRI. AP spine radiographs were examined for symmetry (score difference ≥2 between sides) and morphology of syndesmophytes (typical marginal vs atypical chunky/non-marginal) were compared.

Results: Eight sites contributed 244 (25% HLA-B27+) PsA patients and 198 (75% HLA-B27+) AS patients. Mean BASDAI, mSASSS and PASRI were higher in AS. When categorised by diagnosis and HLA-B27 there were significant differences for age, sex, disease duration, mSASSS, PASRI and syndesmophyte symmetry. Regression analysis, with mSASSS and PASRI as dependent variables revealed significant associations with age, sex, duration of disease, and group (HLA-B27 and diagnosis).

Binary multivariate logistic regression was used to investigate associations of age, sex, HLA-B27 status, diagnosis (PsA v AS) and concomitant diabetes with radiographic features. Sacroiliac symmetry showed no significant associations, whilst syndesmophyte symmetry was associated with increasing age and HLA-B27 positivity. Typical marginal syndesmophytes were associated with age, HLA-B27 status and disease duration: in the cervical spine significant associations with age, sex and HLA-B27 status; in the lumbar spine with HLA-B27 and diagnosis. Atypical chunky syndesmophytes were associated only with increasing age and male sex.

Abstract OP0128 – Table 1

<table>
<thead>
<tr>
<th></th>
<th>Psoriatic arthritis</th>
<th>Ankylosing spondylitis</th>
<th>Statistic</th>
<th>p (2 way)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B27+ (n=184)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y mean (sd)</td>
<td>55.3 (13.4)</td>
<td>50.3 (13.0)</td>
<td>48.5 (14.1)</td>
<td>48.5 (14.3)</td>
</tr>
<tr>
<td>Males n (%)</td>
<td>106 (58)</td>
<td>58 (63)</td>
<td>32 (64)</td>
<td>114 (77)</td>
</tr>
<tr>
<td>Duration of disease, y</td>
<td>11.8 (10.3)</td>
<td>14.2 (11.0)</td>
<td>8.4 (12.3)</td>
<td>9.5 (12.3)</td>
</tr>
<tr>
<td>Symmetry at SU n (%)</td>
<td>165 (90)</td>
<td>54 (90)</td>
<td>43 (86)</td>
<td>132 (89)</td>
</tr>
<tr>
<td>Symmetry in spine n/N</td>
<td>36/62</td>
<td>21/29</td>
<td>14/24</td>
<td>67/84 (109)</td>
</tr>
<tr>
<td>Marginal syndesmophytes, n (%)</td>
<td>58 (72)</td>
<td>39 (65)</td>
<td>25 (50)</td>
<td>89 (60)</td>
</tr>
<tr>
<td>Atypical syndesmophytes, n (%)</td>
<td>41 (22)</td>
<td>17 (28)</td>
<td>12 (24)</td>
<td>29 (20)</td>
</tr>
</tbody>
</table>

* F statistic from one way analysis of variance. +chi squared statistic

Conclusions: This analysis suggests less difference in radiographic phenotype between AS and axial PsA than previously thought. HLA-B27 negative PsA patients have less severe disease as measured by mSASSS and PASRI with less typical marginal syndesmophytes and symmetry, whilst HLA-B27 positive PsA appears similar to AS.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1832

OP0129

DRUG SURVIVAL ON ANTI-TNF-ALPHA IN PSORIATIC ARTHRITIS PATIENTS WITH AXIAL INVOLVEMENT AND ANALYSIS OF PREDICTORS

S. Lopriore, F. Cacciapaglia, S. Perniola, M.G. Anelli, G. Lopalco, C. Scioscia, L. Coladonato, G. Laselva, G. Lapadula, F. Iannone, Department of Emergency and Organ Transplantation (DETO), University of Bari, Rheumatology Unit, Bari, Italy

Background: A few studies have focused on the clinical outcomes in predominant axial Psoriatic Arthritis (PsA) patients treated with anti-TNF-α agents1-3 in real-life settings.

Objectives: Primary endpoint: to evaluate drug survival on anti-TNF-α agents in PsA patients with axial involvement or axial and either polycartilaginous or oligoarticular peripheral arthritis. Secondary endpoints: to evaluate the presence of any predictor of discontinuation of anti-TNF in PsA patients with axial involvement and to investigate whether peripheral arthritis may impact the discontinuation for inefficacy in patients with axial disease.

Methods: 415 biologic therapy-naive PsA patients (CASPAR criteria) starting a biologic therapy-naive PsA patients (CASPAR criteria) starting a

Abstract OP0129 – Figure 1. Drug survival on TNF-Inhibitor in Ax+PsA, Ax+Oligo PsA and Ax+PolyPsA patients. (Kaplan-Meier life table method, log rank test)

Conclusions: PsA subsets seems to have different features, behaviour, clinical response and drug survival on TNF-inhibitors. Ax+Poly PsA subset seems to be more aggressive and difficult to treat. Anti-TNF-α blockers may perform differently in PsA: a more accurate analysis of the clinical disease subsets may improve our knowledge and better management of PsA in daily practice.

REFERENCES:

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7093

OP0130

RISK OF CANCER IN PATIENTS WITH PSORIASIS/PSORIATIC ARTHRITIS: A POPULATION-BASED STUDY IN THE PROVINCE OF BRITISH COLUMBIA

J A Avina-Zubieta1, 2, A. Dominique3, T.A. Simon4, H. Tavakol1, 2. Arthritis Research Canada, Richmond, 3Faculty of Medicine, University of British Columbia, Vancouver, Canada; 4Bristol-Myers Squibb, Princeton, USA

Background: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic arthritis (PsA). PsO/PsA, like other forms of chronic inflammatory arthritis, are often associated with complications such as cardiovascular disease and infections. However, data on the risk of cancer in pts with PsO/PsA at population level are limited.

Objectives: To assess the risk of cancer in pts with newly diagnosed PsO/PsA at the population level.

Methods: We created a population-based matched retrospective cohort of PsO/PsA pts diagnosed between 1 January 1997 and 31 December 2012 using administrative health data from British Columbia, Canada. We identified all incident cases of PsO/PsA and an equal number of controls matched on sex, age and calendar year. PsO/PsA cases met >1 of the following: 1 diagnostic code for PsO/PsA by a rheumatologist/dermatologist; ≥2 diagnostic codes for PsO/PsA, ≥2 months apart in a 2 year period by a non-rheumatologist/dermatologist; or ≥1 hospitalisation with diagnostic code for PsO/PsA. We evaluated incident cancers during follow-up from the Cancer Registry in both cohorts. Adjusted risk of cancers survival was evaluated by Kaplan-Meier life table method, comparison of survival curves with Log-rank test and baseline predictors of drug discontinuation with Cox regression analysis.

Results: At baseline, Axe →Poly PsA patients had significantly higher peripheral (DAPSA) and axial disease activity (BASDAI, ASDAS-CRP). Stratifying patients by subset of disease, the median of treatment was 51 months (95% IQR 24.87–77.13) for Axe→PsA group, 50 months (95% IQR 28.39–71.61) for Axe→Oligo PsA group, 30 months (95% IQR 11.84–48.15) for Axe→Poly PsA group (figure 1).

Axe→Oligo PsA patients had significantly higher persistence on TNFi rather than Axe→Poly PsA patients (log rank test, p=0.03). Axe→Poly PsA patients had higher risk of stopping TNFi (Cox regression, HR 3.75) and significantly higher percentage of discontinuation for ineffectiveness rather than for an adverse event (χ2 test, p=0.0009).

At last observation, Axe→Poly PsA patients had higher DAPSA but no difference in axial disease activity (t-STUDENT test, Mann-Whitney test).

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7093